Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS

Susan E. Buskin, Laura M. Newcomer, Laura A. Koutsky, Thomas Hooton, David H. Spach, Sharon G. Hopkins

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

To measure the effect of trimethoprim-sulfamethoxazole (TMP-SMX) in preventing bacterial illness, Pneumocystis carinii pneumonia (PCP), and death in people with AIDS, we conducted a retrospective medical record review of 1078 persons who were observed for 3 years on average who attended nine outpatient facilities in Seattle, Washington between January 1990 and April 1996. We calculated relative risk estimates to measure the protective effect of TMP-SMX on the development of major bacterial illnesses, PCP, and death. Use of TMP-SMX decreased the risk of PCP (relative risk [RR] = 0.23; 95% confidence interval [CI], 0.14-0.36) and deaths not attributable to PCP (RR = 0.59; 95% CI, 0.47-0.73). Prevention of major bacterial illnesses of known etiology was of borderline significance (RR = 0.77; 95% CI, 0.57-1.05) and became statistically significant with the addition of patients with infections of unknown etiology (RR = 0.77; 95% CI 0.61-0.97). Use of TMP-SMX PCP prophylaxis significantly reduced the risks of death and of PCP and was associated with a trend toward reduced risk of major bacterial infections.

Original languageEnglish
Pages (from-to)201-206
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume20
Issue number2
StatePublished - Feb 1 1999
Externally publishedYes

Fingerprint

Pneumocystis Pneumonia
Sulfamethoxazole Drug Combination Trimethoprim
Acquired Immunodeficiency Syndrome
Confidence Intervals
Bacterial Infections
Medical Records
Outpatients
Infection

Keywords

  • AIDS mortality
  • Bacterial infections
  • HIV infection
  • Pneumocystis carinii pneumonia
  • Trimethoprim- sulfamethoxazole

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS. / Buskin, Susan E.; Newcomer, Laura M.; Koutsky, Laura A.; Hooton, Thomas; Spach, David H.; Hopkins, Sharon G.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 20, No. 2, 01.02.1999, p. 201-206.

Research output: Contribution to journalArticle

@article{81f6b2f92d724c17b390c926670829a2,
title = "Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS",
abstract = "To measure the effect of trimethoprim-sulfamethoxazole (TMP-SMX) in preventing bacterial illness, Pneumocystis carinii pneumonia (PCP), and death in people with AIDS, we conducted a retrospective medical record review of 1078 persons who were observed for 3 years on average who attended nine outpatient facilities in Seattle, Washington between January 1990 and April 1996. We calculated relative risk estimates to measure the protective effect of TMP-SMX on the development of major bacterial illnesses, PCP, and death. Use of TMP-SMX decreased the risk of PCP (relative risk [RR] = 0.23; 95{\%} confidence interval [CI], 0.14-0.36) and deaths not attributable to PCP (RR = 0.59; 95{\%} CI, 0.47-0.73). Prevention of major bacterial illnesses of known etiology was of borderline significance (RR = 0.77; 95{\%} CI, 0.57-1.05) and became statistically significant with the addition of patients with infections of unknown etiology (RR = 0.77; 95{\%} CI 0.61-0.97). Use of TMP-SMX PCP prophylaxis significantly reduced the risks of death and of PCP and was associated with a trend toward reduced risk of major bacterial infections.",
keywords = "AIDS mortality, Bacterial infections, HIV infection, Pneumocystis carinii pneumonia, Trimethoprim- sulfamethoxazole",
author = "Buskin, {Susan E.} and Newcomer, {Laura M.} and Koutsky, {Laura A.} and Thomas Hooton and Spach, {David H.} and Hopkins, {Sharon G.}",
year = "1999",
month = "2",
day = "1",
language = "English",
volume = "20",
pages = "201--206",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS

AU - Buskin, Susan E.

AU - Newcomer, Laura M.

AU - Koutsky, Laura A.

AU - Hooton, Thomas

AU - Spach, David H.

AU - Hopkins, Sharon G.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - To measure the effect of trimethoprim-sulfamethoxazole (TMP-SMX) in preventing bacterial illness, Pneumocystis carinii pneumonia (PCP), and death in people with AIDS, we conducted a retrospective medical record review of 1078 persons who were observed for 3 years on average who attended nine outpatient facilities in Seattle, Washington between January 1990 and April 1996. We calculated relative risk estimates to measure the protective effect of TMP-SMX on the development of major bacterial illnesses, PCP, and death. Use of TMP-SMX decreased the risk of PCP (relative risk [RR] = 0.23; 95% confidence interval [CI], 0.14-0.36) and deaths not attributable to PCP (RR = 0.59; 95% CI, 0.47-0.73). Prevention of major bacterial illnesses of known etiology was of borderline significance (RR = 0.77; 95% CI, 0.57-1.05) and became statistically significant with the addition of patients with infections of unknown etiology (RR = 0.77; 95% CI 0.61-0.97). Use of TMP-SMX PCP prophylaxis significantly reduced the risks of death and of PCP and was associated with a trend toward reduced risk of major bacterial infections.

AB - To measure the effect of trimethoprim-sulfamethoxazole (TMP-SMX) in preventing bacterial illness, Pneumocystis carinii pneumonia (PCP), and death in people with AIDS, we conducted a retrospective medical record review of 1078 persons who were observed for 3 years on average who attended nine outpatient facilities in Seattle, Washington between January 1990 and April 1996. We calculated relative risk estimates to measure the protective effect of TMP-SMX on the development of major bacterial illnesses, PCP, and death. Use of TMP-SMX decreased the risk of PCP (relative risk [RR] = 0.23; 95% confidence interval [CI], 0.14-0.36) and deaths not attributable to PCP (RR = 0.59; 95% CI, 0.47-0.73). Prevention of major bacterial illnesses of known etiology was of borderline significance (RR = 0.77; 95% CI, 0.57-1.05) and became statistically significant with the addition of patients with infections of unknown etiology (RR = 0.77; 95% CI 0.61-0.97). Use of TMP-SMX PCP prophylaxis significantly reduced the risks of death and of PCP and was associated with a trend toward reduced risk of major bacterial infections.

KW - AIDS mortality

KW - Bacterial infections

KW - HIV infection

KW - Pneumocystis carinii pneumonia

KW - Trimethoprim- sulfamethoxazole

UR - http://www.scopus.com/inward/record.url?scp=0033080881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033080881&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 201

EP - 206

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 2

ER -